Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Azacitidine and DLI in AML Relapse After Allo-HSCT
NCT05772273Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Response Rate at 39 days. Started Mar 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05772273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772273.